Stocktwits on MSN

This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling

Tradipitant is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. ・The drug is also being ...
BioSpace

FDA Action Alert: GSK, Aldeyra, Rhythm and More

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...
FiercePharma

After FDA rejection, Vanda sues agency over regulatory rebuffs on jet lag med

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...
Schaeffer's Investment Research

Vanda Pharmaceuticals Stock Rallies on FDA Filing

Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, ...
FiercePharma

Vanda rejects buyout offers, pans 'opportunistic attempts' at securing its shares at a discount

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...
Yahoo Finance

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration ...
FierceBiotech

Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the ...
TipRanks on MSN

Vanda Pharmaceuticals announces submission of BLA to FDA for imsidolimab

Vanda Pharmaceuticals (VNDA) announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for ...
Healio

Vanda’s tradipitant falls short for gastroparesis as FDA requests ‘additional studies’

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the ...
Yahoo Finance

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing ...
Benzinga.com

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...